PAN Board Member and CEO of The Parkinson Alliance, Carol Walton, has been selected for the National Medical Device Postmarket Surveillance System Planning Board.
The 16-member planning board includes individuals from a range of nonprofit organizations and federal agencies and will be convened by The Brookings Institution as part of a cooperative agreement with the U.S. Food and Drug Administration (FDA). The planning board will identify actionable strategies to support the development and implementation of a National Medical Device Postmarket Surveillance System, which supports the safety and effectiveness of medical devices and enables a wide range of activities to improve clinical practice and quality outcomes for patients.
PAN nominated Carol for this important position. As a leader in the Parkinson’s community, Carol has dedicated much of her work to understanding the patient perspective on Deep Brain Stimulation (DBS), a surgically implanted device used to treat the debilitating symptoms of Parkinson’s disease, such as tremor, rigidity, stiffness, slowed movement, and walking problems. Since 2001, The Parkinson Alliance has conducted 18 surveys with people with Parkinson’s to assess quality of life with Parkinson’s and after DBS. Carol will bring a unique perspective to the board due to her work understanding patient views on what a device can mean to quality of life.